During #ASCO26, I spoke with Dr. Patrick Hwu (@PatrickHwuMD ), Moffitt Cancer Center President & CEO about research aimed at improving treatment for brain tumors and melanoma that spreads to the brain. #ASCO26 #MoffittASCO26 @MoffittNews

While at #ASCO26, Peter Forsyth, MD (@PeterForsyth27), stopped by the booth to share research exploring patient-derived tumor models to identify potential treatment strategies for melanoma leptomeningeal disease. #MoffittASCO26

🚨New phase 3 data presented at #ASCO26 compared postoperative stereotactic radiation with cesium-131 tile-based radiation following resection of brain metastases. Moffitt’s Peter Forsyth, MD (@PeterForsyth27), discusses the work by @DrJeffWeinberg of @UTMDAnderson and how tile-based radiation could help redefine postoperative care by improving local control and integrating surgery and radiation into a single treatment approach. #MoffittASCO26 x.com/MoffittNews/status/206…

From #ASCO26, Peter Forsyth, MD (@PeterForsyth27), and Brian Czerniecki, MD, PhD (@BCzernieckiMD), discuss the power of cross-disciplinary collaboration in advancing cancer care. Their work combines expertise in neuro-oncology and immunotherapy to develop dendritic cell-based treatments for leptomeningeal disease in patients with breast cancer, with a phase 2 clinical trial now underway. #MoffittASCO26 x.com/MoffittNews/status/206…

From #ASCO26, Peter Forsyth, MD (@PeterForsyth27), and Muhammad Jaffer, MD, discuss advances in neuro-oncology, including long-term follow-up from the INDIGO trial showing durable benefits for patients with low-grade glioma and continued momentum toward earlier intervention. They also highlight research focused on understanding and reducing neurologic toxicities associated with cancer therapies, with the goal of preserving quality of life while improving outcomes. #MoffittASCO26 x.com/MoffittNews/status/206…

Dendritic Cell Trial Brings Hope for Young Mom With Leptomeningeal Disease | Moffitt @MoffitNews moffitt.org/endeavor/archive…

Pics from March 13.

On March 13 we discussed what we learn from autopsies on patients with leptomeningeal disease (LMD) and how important they are for discovering new and better treatments for this disease. It's an emotional issue, and it's not for everyone-but it's a precious gift that will help us develop cures. I'm going to donate my body to science when my turn comes, but it's a personal decision. We had the first example where we gathered as a group medically and talked about the patient's clinical history. We analyzed what we thought was going on in life, reviewed the radiology studies in detail, and finally the autopsy findings to see what was actually happening in the leptomeningeal. In this case, as we suspected clinically, it wasn't real LMD. So we have refined our diagnostic accuracy. And more to the point, we would not use these tissues to test and discover new targets for effective LMD treatment. A critical critical component in discovering cures for this terrible disease.

We are very grateful to Moffitt for recognizing our success in building (and funding) our LMD Program as one of the Top Research Stories of the year! And very lucky to be in this rich environment of discovery and super enthusiastic collaborations make our transdisciplinary work possible! It’s a magical place for discovery in cancer. Thank you all for the great Team and Dr. Brian Czernicki’s MD PhD. fundamental discoveries in Dendritic Cell Therapies that drive our collaborations. And the other top story is from Dr. Greg Sawyer PhD and his wonderful engineering and imaging center which is unique and world class. We are working now on developing models and new treatments for LMD that are unique and exploiting engineering expertise to understanding this major clinical challenge. It is really, fundamentally an engineering problem so best to get engineers working on it. @MoffittNews

Golfers Vs. Brain Cancer in Oldsmar was an incredible event! @MoffittNews

Great Miles for Moffitt turn out. @MoffittNews

Miles for Moffitt. Go Team Transformers! @MoffittNews

Miles for Moffitt. Great Event! @MoffittNews

At #SNO2025, Vincent Law (@Binzento) shares a first-in-human trial of intrathecal cDC1 therapy for breast cancer leptomeningeal disease. Early results show safety and Th1-driven immune activation, with expanded T and B cells, reduced CSF tumor burden. Eighty-three percent of patients maintained or improved their performance status. #MoffittSNO2025

What an incredible few days at #SITC25 with the @MoffittNews team and colleagues from around the world! ✨ I’m truly inspired by the science, passion, and collaboration driving the future of immunotherapy. Catch the highlights from the conference in the latest ImmunoVerse Podcast Bonus Episode, recorded live at the @sitcancer Annual Meeting with @DemariaLab_WCM! 🎙️ Tune in today: bit.ly/3JqfSfb #MoffittSITC25 #Immunotherapy #CancerResearch

What is leptomeningeal disease? Peter Forsyth, MD (@PeterForsyth27) joins Patrick Hwu, MD (@PatrickHwuMD) to discuss the latest immunotherapy research for the treatment of leptomeningeal disease.

Great meeting at SITC and the Melanoma Research Foundation had their fourth meeting dedicated to basic, translational and clinical research on melanoma brain metastases. The first one I attended was in 2015. The meeting started with a patient testimony from a long-term survivor from symptomatic melanoma brain mets that was treated on checkmate 204 with ipi nivo and is apparently cured. He is an inspiration and reminded us why we do what we do. Great research talks and summaries by the worlds experts and leaders in the field. Great talk from Dr. Inna Smalley about LMD! Great meeting and I learned a lot. Very grateful to MRF for arranging this important meeting! @MoffittNews